SGLT2i for Mitral Regurgitation; Mining Angiograms With AI; Melatonin and CVD Risk?
Med Page Today
MAY 7, 2024
(MedPage Today) -- The Apple Watch atrial fibrillation feature got added to FDA's list of qualified devices for use in clinical studies. (Mashable) The SGLT2 inhibitor ertugliflozin (Steglatro) showed promise for the reduction of functional mitral.
Let's personalize your content